Research ArticleExperimental Studies
Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response
AVITAL GRANIT MIZRAHI, HANEEN HAMAD, AHINOAM GUGENHEIM, BENJAMIN NISMAN, ANNA KUZNETZ, INNA BEN DAVID, YAEL GELFEND, SHERRI COHEN, AVIAD ZICK, KIM SHEVA, HOVAV NECHUSHTAN, TAMAR PERETZ and AMICHAY MEIROVITZ
Anticancer Research November 2022, 42 (11) 5257-5263; DOI: https://doi.org/10.21873/anticanres.16032
AVITAL GRANIT MIZRAHI
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
2Faculty of Medicine, Hebrew University, Jerusalem, Israel;
HANEEN HAMAD
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
AHINOAM GUGENHEIM
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
BENJAMIN NISMAN
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
ANNA KUZNETZ
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
INNA BEN DAVID
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
YAEL GELFEND
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
SHERRI COHEN
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
AVIAD ZICK
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
2Faculty of Medicine, Hebrew University, Jerusalem, Israel;
KIM SHEVA
3The Legacy Heritage Oncology Center and Dr. Larry Norton Institute, Soroka University Medical Center, Be’er Sheva, Israel;
HOVAV NECHUSHTAN
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
TAMAR PERETZ
1Oncology Laboratory, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
2Faculty of Medicine, Hebrew University, Jerusalem, Israel;
AMICHAY MEIROVITZ
3The Legacy Heritage Oncology Center and Dr. Larry Norton Institute, Soroka University Medical Center, Be’er Sheva, Israel;
4Ben Gurion University of the Negev, Be’er Sheva, Israel
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
patientACCESS
patientACCESS - Patients desiring access to articles
In this issue
Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response
AVITAL GRANIT MIZRAHI, HANEEN HAMAD, AHINOAM GUGENHEIM, BENJAMIN NISMAN, ANNA KUZNETZ, INNA BEN DAVID, YAEL GELFEND, SHERRI COHEN, AVIAD ZICK, KIM SHEVA, HOVAV NECHUSHTAN, TAMAR PERETZ, AMICHAY MEIROVITZ
Anticancer Research Nov 2022, 42 (11) 5257-5263; DOI: 10.21873/anticanres.16032
Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response
AVITAL GRANIT MIZRAHI, HANEEN HAMAD, AHINOAM GUGENHEIM, BENJAMIN NISMAN, ANNA KUZNETZ, INNA BEN DAVID, YAEL GELFEND, SHERRI COHEN, AVIAD ZICK, KIM SHEVA, HOVAV NECHUSHTAN, TAMAR PERETZ, AMICHAY MEIROVITZ
Anticancer Research Nov 2022, 42 (11) 5257-5263; DOI: 10.21873/anticanres.16032
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.